Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure
- 14 January 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 26 (2), 185-192
- https://doi.org/10.1097/qad.0b013e32834e9d7d
Abstract
Objectives: To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI resistance mutations. Design: Pooled analysis of the risk of virologic failure conferred by minority NNRTI resistance mutations and NNRTI adherence from three studies of treatment-naïve individuals initiating an NNRTI-based regimen. Methods: Participants from each study were categorized into both adherence quartiles (Q1–Q4) and four strata: at least 95%, 80–94%, 60–79%, and below 60%. Weighted Cox proportional hazard models were used to estimate the risk of virologic failure. Results: The majority of participants (N = 768) had high measured adherence, but those in the lowest adherence quartile had the highest proportion of participants with virologic failure and the risk of virologic failure increased step-wise with adherence below 95%. Detection of minority NNRTI drug resistance mutations increased the proportion of participants with virologic failure across adherence quartiles (Cochran–Mantel–Haenszel P < 0.001) and adherence strata [Cochran–Mantel–Haenszel P < 0.001; P = 0.02; 60–79% adherence, hazard ratio 1.2 (0.5–3.2), P = 0.67; 80–94% adherence, hazard ratio 2.5 (0.98–6.3), P = 0.06; ≥95% adherence, hazard ratio 3.6 (2.3–5.6), P < 0.001]. On multivariate analysis, the effect of minority variants was also most prominent at higher levels of medication adherence. Conclusions: The presence of minority NNRTI resistance mutations and NNRTI adherence were found to be independent predictors of virologic failure, but also modify each other's effects on virologic failure. In addition to the focus on medication adherence counseling, ultrasensitive HIV-1 drug resistance assays could play a role in optimizing the success rates of first-line antiretroviral therapy.Keywords
This publication has 23 references indexed in Scilit:
- Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment FailureJAMA, 2011
- Retention in HIV Care for Individuals Not Yet Eligible for Antiretroviral Therapy: Rural KwaZulu-Natal, South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapyAIDS, 2011
- An update on the use of Atripla® in the treatment of HIV in the United StatesHIV/AIDS - Research and Palliative Care, 2010
- Antiretroviral Prescribing Patterns in Treatment-Naïve Patients in the United StatesAIDS Patient Care and STDs, 2010
- Pre‐existing Minority Drug‐Resistant HIV‐1 Variants, Adherence, and Risk of Antiretroviral Treatment FailureThe Journal of Infectious Diseases, 2010
- CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?AIDS Research and Therapy, 2010
- Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the CaribbeanJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Less Than 95% Adherence to Nonnucleoside Reverse‐Transcriptase Inhibitor Therapy Can Lead to Viral SuppressionClinical Infectious Diseases, 2006
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004